CA2137363C - Utilisation de glycoproteines de la membrane pellucide a des fins d'immunocontraception - Google Patents

Utilisation de glycoproteines de la membrane pellucide a des fins d'immunocontraception

Info

Publication number
CA2137363C
CA2137363C CA002137363A CA2137363A CA2137363C CA 2137363 C CA2137363 C CA 2137363C CA 002137363 A CA002137363 A CA 002137363A CA 2137363 A CA2137363 A CA 2137363A CA 2137363 C CA2137363 C CA 2137363C
Authority
CA
Canada
Prior art keywords
zona pellucida
vaccine
seals
adjuvant
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002137363A
Other languages
English (en)
Other versions
CA2137363A1 (fr
Inventor
Robert Brown
Warwick Kimmins
Michael Mezei
Bill Pohajdak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunovaccine Technologies Inc
Original Assignee
Dalhousie University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dalhousie University filed Critical Dalhousie University
Publication of CA2137363A1 publication Critical patent/CA2137363A1/fr
Application granted granted Critical
Publication of CA2137363C publication Critical patent/CA2137363C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002137363A 1992-06-05 1993-06-07 Utilisation de glycoproteines de la membrane pellucide a des fins d'immunocontraception Expired - Fee Related CA2137363C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89280792A 1992-06-05 1992-06-05
US892,807 1992-06-05
PCT/CA1993/000239 WO1993025231A1 (fr) 1992-06-05 1993-06-07 Utilisation de glycoproteines de la zone pellucide dans l'immunocontraception

Publications (2)

Publication Number Publication Date
CA2137363A1 CA2137363A1 (fr) 1993-12-23
CA2137363C true CA2137363C (fr) 1999-06-15

Family

ID=25400523

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002137363A Expired - Fee Related CA2137363C (fr) 1992-06-05 1993-06-07 Utilisation de glycoproteines de la membrane pellucide a des fins d'immunocontraception

Country Status (3)

Country Link
AU (1) AU4303493A (fr)
CA (1) CA2137363C (fr)
WO (1) WO1993025231A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9498493B2 (en) 2007-09-27 2016-11-22 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US10105435B2 (en) 2011-10-06 2018-10-23 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
US10272042B2 (en) 2005-10-07 2019-04-30 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037100A2 (fr) * 1998-12-22 2000-06-29 Dalhousie University Compositions et procedes pour reduire ou prevenir la fertilisation chez des poissons et des oiseaux
CA2378478A1 (fr) * 1999-07-01 2001-01-11 The University Of Georgia Research Foundation, Inc. Vaccin anti-fecondite contenant une proteine de membrane pellucide aviaire et procede d'utilisation
AU5909500A (en) * 1999-07-01 2001-01-22 University Of Georgia Research Foundation, Inc., The Method and composition for affecting reproductive systems
CA2428103C (fr) 2000-11-07 2015-06-09 Immunovaccine Technologies Inc. Vaccins a reponse immunitaire accrue et leurs procedes de preparation
CN102056622B (zh) 2008-06-05 2016-04-06 免疫疫苗技术有限公司 包含脂质体、抗原、多核苷酸和含疏水物质的连续相的载体的组合物
BRPI0919174B1 (pt) 2008-09-17 2020-11-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention vírus da raiva recombinante, composição imunogênica e seu uso

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1504259A (en) * 1976-07-19 1978-03-15 Merck & Co Inc Immunological control of fertility
US4996297A (en) * 1987-10-07 1991-02-26 Zonagen, Inc. Recombinantly expressed rabbit zona pellucida polypeptides

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272042B2 (en) 2005-10-07 2019-04-30 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment
US9498493B2 (en) 2007-09-27 2016-11-22 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US10232052B2 (en) 2007-09-27 2019-03-19 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US10105435B2 (en) 2011-10-06 2018-10-23 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof

Also Published As

Publication number Publication date
WO1993025231A1 (fr) 1993-12-23
AU4303493A (en) 1994-01-04
CA2137363A1 (fr) 1993-12-23

Similar Documents

Publication Publication Date Title
EP1140165B1 (fr) Compositions adjuvantes ameliorees a base de saponine et procedes en rapport
ES2258108T3 (es) Vacunas con respuesta inmune mejorada y procedimientos de preparacion de las mismas.
DE69935152T2 (de) Durch zelloberflächenmoleküle induzierte makrophagenaktivierung
UA56132C2 (uk) Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5736141A (en) Method to prevent fertilization in mammals by administering a single dose of zona pellucida derived antigens, liposome and Freund's adjuvant
WO1994007469A1 (fr) Immunorenforçateur pour liberation differee d'un immunogene
USRE37224E1 (en) Method to prevent fertilization in mammals by administering a single dose of zona pellucida derived antigens, liposome and adjuvant
WO1993025231A1 (fr) Utilisation de glycoproteines de la zone pellucide dans l'immunocontraception
CA2352563C (fr) Methode de preparation de vaccins inactives associes a une emulsion eau dans huile adjuvante
AU2010364538B2 (en) Human lactoferrin derived peptide for use as an antigen masking agent
Ferro et al. Immune responses to a GnRH-based anti-fertility immunogen, induced by different adjuvants and subsequent effect on vaccine efficacy
CN107073086B (zh) 免疫性lhrh组合物及其在猪只中的应用
Bechert et al. Immune response of African elephants to a single dose of SpayVac®, a pZP contraceptive vaccine, over a seven year period
JPH11515013A (ja) 合成複合ワクチンの免疫原性担体としてのシュードモナスエクソトキシン
Miller Delivery of Immunocontraceptive Vaccines
IE50857B1 (en) Control of ovulation
WO1999034825A1 (fr) Vaccin anti-fecondite et mode d'utilisation
Eski et al. INVESTIGATION OF THE IMMUNOCASTRATION EFFICACY AND LONGEVITY OF A SINGLE DOSE GNRH VACCINE IN YOUNG MALE RATS
CA2378478A1 (fr) Vaccin anti-fecondite contenant une proteine de membrane pellucide aviaire et procede d'utilisation
WO2008110912A1 (fr) Régulation de fertilité chez des chevaux
HK1196379B (en) Human lactoferrin derived peptide for use as an antigen masking agent
WO1996037178A2 (fr) Nouveau procede pour accroitre l'efficacite d'agents anti-arthropodes contre les ectoparasites se nourrissant du sang

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed